U.S. Markets closed

Osyka Corporation (OSKA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0435+0.0235 (+117.50%)
At close: 3:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0200
Open0.0230
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0230 - 0.0487
52 Week Range0.0015 - 0.0487
Volume1,030,629
Avg. Volume57,241
Market Cap13.666M
Beta (5Y Monthly)-0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.0660
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021

    Press Release 22 January 2021 Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021 At the Extraordinary General Meeting (the “EGM”) of Immunicum AB (publ) (IMMU.ST) on 22 January 2021 the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the EGM and the complete proposals, which have previously been published and are available on the company’s website, www.immunicum.com. Election of Board of Directors and approval of remuneration to the Board Prior to the EGM, Van Herk Investments B.V. (“Van Herk”) had proposed that the Board would be composed of eight (8) ordinary board members without deputies through election of Dharminder Chahal and Andrea van Elsas as new board members and that current chairman Michael Oredsson and the board members Sven Andreasson, Charlotte Edenius, Steven Glazer, Christine Lind and Helén Tuvesson would remain in the Board. In light of Michael Oredsson’s resignation from his position as chairman, as well as the Board’s appointment of Christine Lind as interim chairman for the period until the next Annual General Meeting as announced by press release on 21 January 2021, the EGM resolved that the Board shall be composed of seven (7) ordinary board members without deputies. The EGM resolved to elect Dharminder Chahal and Andrea van Elsas as new board members and that Sven Andreasson, Charlotte Edenius, Steven Glazer, Christine Lind and Helén Tuvesson shall remain in the Board for the period until the next Annual General Meeting. Further, it was resolved in accordance with Van Herk’s proposal that Andrea van Elsas and Dharminder Chahal shall receive the same remuneration as the other board members in the company, i.e., SEK 150,000 on an annual basis. The remuneration shall be adjusted pro rata based on the time from their election as board members up until the Annual General Meeting 2021. The information in this press release is information that Immunicum AB (publ) is obliged to disclose pursuant to Nasdaq Stockholm’s Rule Book for Issuers. The information was released for public disclosure through the contact person detailed below on 22 January 2021 at 14:00 CET. For more information, please contact: Christine Lind, Interim Chairman of the Board of DirectorsTelephone: +46 8 732 8400E-mail: ir@immunicum.com About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com Attachment 20210122 Immunicum EGM Report (Delphi 210121)(16740248.1)_FINAL

  • GlobeNewswire

    Immunicum AB (publ) Announces Transitions in Board of Directors

    Press Release 21 January 2021 Immunicum AB (publ) Announces Transitions in Board of Directors Immunicum AB (publ: IMMU.ST) today announced that Michael Oredsson has decided to resign his position as chairman and member of Immunicum’s Board of Directors, effective as of the Extraordinary General Meeting (EGM) that will be held tomorrow on January 22, 2021. The Board has agreed to appoint Christine Lind, currently serving as board member, as interim chairman until the next Annual General Meeting (AGM), to be held on May 4, 2021. “I have been part of Immunicum’s development since 2018 and have been very encouraged by the clinical progress and achievements over the past years,” commented Michael Oredsson. “For the next stage of Immunicum’s transformation, it is an appropriate time to hand over the chairman role and I am confident that the Company can benefit from the wealth of experience that Christine has in guiding strategy and bringing together expertise to build value in biopharmaceutical companies.” “On behalf of the entire board, I would like to thank Michael for his tireless support and significant contributions to Immunicum over the past years,” said Christine Lind. “His dedication to ensuring that Immunicum’s programs continue to move toward commercialization and reach patients has been essential for the advancement of the company. With the combined strengths following the recent business combination and both ilixadencel and DCP-001 in clinical development, I am excited about Immunicum’s potential to bring future treatments to patients. I am honored to work with my fellow board members and Immunicum’s executive team to build Immunicum’s position as a leader in cell-based therapies.” At the EGM, as previously announced, it is proposed is to elect Dharminder Chahal and Andrea van Elsas, Ph.D., as new members of the Board of Directors. If the vote at the EGM is in favor of these elections, the board will be composed of Christine Lind as interim chairman, and Sven Andreasson, Dharminder Chahal, Charlotte Edenius M.D., Ph.D., Andrea van Elsas Ph.D., Steven Glazer M.D., and Helén Tuvesson Ph.D., as members for the period until the AGM. The information is such information that Immunicum is obliged to make public pursuant to EU Market Abuse Regulation. The information was released for public disclosure through the contact persons detailed below on 21 January 2021, at 08:00 am CET. For more information, please contact: Michael Oredsson and Christine LindTelephone: +46 8 732 8400E-mail: ir@immunicum.com About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com Attachment 20210121_Immunicum BoD Announcement_ENG_FINAL

  • Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)
    GlobeNewswire

    Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)

    Press Release 31 December 2020Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC) Immunicum AB (publ; IMMU.ST) announced today that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the Company’s lead candidate, ilixadencel, a cell-based, off-the-shelf immune primer, for the treatment of Hepatocellular Carcinoma (HCC). The designation was based on data from a Phase I/II clinical trial of ilixadencel in patients with unresectable and/or metastatic HCC. The Orphan Drug Act was enacted in the United States to support the development of new drugs and biologics for rare diseases through financial incentives, such as partial tax credit for clinical trial costs, and up to seven years of market exclusivity upon regulatory product approval.“Our efforts to secure the most advantageous conditions for the further clinical development of ilixadencel based on its broad potential in a range of solid tumor indications continue to be successful,” said Sven Rohmann, M.D., Ph.D., CEO of Immunicum. “As we become a fully-integrated biopharmaceutical company and further define our plans for ilixadencel’s path toward commercialization, it is valuable to complement this year’s Fast Track and RMAT designations with today’s FDA Orphan Drug Designation.”In May 2020, Immunicum received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for ilixadencel to be used for treatment of patients with metastatic Renal Cell Carcinoma. In December 2020, Immunicum announced that it received Fast Track Designation from the U.S. FDA for ilixadencel as a treatment for Gastrointestinal Stromal Tumors (GIST).The information is such information that Immunicum is obliged to make public pursuant to EU Market Abuse Regulation. The information was released for public disclosure through the contact persons detailed below on 31 December 2020 at 2:00 pm CET.About ilixadencel Ilixadencel is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Injection of these cells in the patient’s tumor generates an inflammatory response which in turns leads to tumor-specific activation of the patient’s cytotoxic T cells. To-date ilixadencel has been tested in a range of clinical trials in various solid tumor indications including metastatic Renal Cell Carcinoma (mRCC), hepatocellular carcinoma (HCC) and gastrointestinal stromal tumors (GIST) and in combination with several standard-of-care cancer therapies such as the tyrosine kinase inhibitors Sutent® (sunitinib) and Stivarga® (regorafenib), and the checkpoint inhibitor Keytruda® (pembrolizumab). Ilixadencel has consistently maintained a positive safety and tolerability profile and demonstrated initial signs of efficacy as seen in the randomized Phase II MERECA trial. Ilixadencel is currently moving towards late-stage clinical development.About Hepatocellular Carcinoma Hepatocellular carcinoma (HCC) is a rare indication and yet the most common cause of death in people with liver cirrhosis. Progression is very rapid and prognosis is poor due to the inability to completely remove the tumor through surgery in most cases. Malignant transformation of liver cells may occur as a consequence of various origins, such as chronic viral hepatitis, alcohol and metabolic disorders.For more information, please contact:Sven Rohmann, M.D., Ph.D., CEO Telephone: +46 8 732 8400 E-mail: info@immunicum.com  INVESTOR RELATIONS Jonas Rodny and Carolin Wiken Paues Åberg Communications Telephone: +46 76 190 90 51 E-mail: ir@immunicum.com Media RelationsEva Mulder and Sophia Hergenhan, Ph.D. Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com About Immunicum AB (publ)Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The Company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.comAttachment * 20201231_Immunicum FDA_ODD_ENG_Final